Lisata provides financials of acquired Cend; CEND-1 in Phase 2b for pancreatic cancer

LISATA THERAPEUTICS, INC.

Merger of Cend into Lisata completed Sep 14, 2022; this amendment provides historical and pro forma financials of Cend.
Cend's lead drug CEND-1 (iRGD peptide) in Phase 2b for 1L metastatic PDAC; Phase 1b showed promising safety and efficacy.
Cend collaboration with Qilu Pharma for Greater China: $10M upfront, up to $225M in milestones, tiered royalties 10-15%.
Cend recorded net income in 2021 from one-time license payment, but otherwise incurred losses since inception.
Unaudited interim financials of Cend as of June 30, 2022 and pro forma combined financials of Lisata are filed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.